Main menu

Recent Pfizer Press Releases

3/3/15 8:35am EST
Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

Label Also Updated to Include Data From the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Pfizer Inc.

more...
2/26/15 12:29pm EST
CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

Pfizer Inc. (NYSE: PFE) announced today that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend serogroup B meningococcal vaccination to help protect individuals at increased risk. Specifically, the ACIP voted to recommend serogroup B meningococcal vaccination for persons aged 10 years and older at increased risk for meningococcal disease, including:

more...
2/24/15 8:00am EST
2/20/15 10:30am EST
FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application (sNDA)for RAPAMUNE® (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease in women of childbearing age that is often fatal.

more...
2/13/15 10:27am EST
Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride), extended-release capsules, an abuse-deterrent formulation (ADF) opioid for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ALO-02 is an extended-release oxycodone specifically designed to reduce abuse via the oral, intranasal (i.e., snorting) and intravenous (IV) routes when crushed.

more...
2/12/15 10:35am EST
Safety and Efficacy of ELELYSO® (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015

Pfizer Inc. (NYSE: PFE) today announced that researchers presented new data which expand on the existing body of data for ELELYSO (taliglucerase alfa) for injection in pediatric patients with Type 1 Gaucher disease.  These data, which were released today in an oral presentation at the 11th Annual WORLDSymposium in Orlando, include results from a Phase 3, multi-center, extension trial evaluating the long-term efficacy and safety of ELELYSO in pediatric patients with Type 1 Gaucher disease who were treatment-naïve or previously treated with imiglucerase. 

more...
2/9/15 5:27pm EST
Pfizer Commences $5 Billion Accelerated Share Repurchase

Accelerated Share Repurchase Assumed in Pfizer’s 2015 Financial Guidance Issued on January 27, 2015

2/5/15 7:01am EST
Pfizer to Acquire Hospira

  • Transaction will significantly enhance Pfizer’s Global Established Pharmaceutical (GEP) Business
  • Transaction valued at $90 per Hospira share, for a total enterprise value of approximately $17 billion
  • Expected to be immediately accretive upon closing; $0.10-$0.12 accretion expected in first full year after close with additional accretion anticipated thereafter

 

 

Pfizer Inc. (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion. 

more...
2/5/15 6:58am EST
Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Pfizer's Proposed Acquisition of Hospira

Pfizer will hold an analyst and investor call to discuss its proposed acquisition of Hospira at 9:00 AM EST (2:00 PM GMT) today, February 5, 2015. Pfizer will also hold a media call at 10:15 AM EST (3:15 PM GMT) today, February 5, 2015.

more...
2/4/15 8:00am EST
Pfizer Marks World Cancer Day With Grant To Union For International Cancer Control To Address The Needs Of Metastatic Breast Cancer Patients

Citing the Need for More Support for Metastatic Breast Cancer Patients, Pfizer Pledges $500,000 (USD) in Funding for International Grants Program

 

 

Pfizer Inc. today announced a grant to the Union for International Cancer Control (UICC) for a first-of-its-kind initiative to address the unique challenges facing metastatic breast cancer (MBC) patients.

more...
2/3/15 6:00pm EST
Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib)

 

First Cyclin-Dependent Kinase 4/6 (CDK 4/6) Inhibitor Approved by the FDA 
- - - 
IBRANCE Now Available for Use in Combination with Letrozole as First-Line Treatment of Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer

Pfizer Inc. today announced the U.S.

more...
1/27/15 7:00am EST
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE

more...
1/26/15 4:12pm EST
Pfizer Commits to Further Reduce Price for Prevenar 13 in the World’s Poorest Countries Through 2025

Pfizer Announces New Commitments During Gavi’s Pledging Conference

Pfizer Inc. (NYSE:PFE) today announced new commitments aimed at ensuring the world’s most resource-limited countries have access to Prevenar 13* (pneumococcal polysaccharide conjugate vaccine (PCV), 13 – valent, absorbed) through Gavi, the Vaccine Alliance. Pfizer’s commitments were announced during Gavi’s pledging conference being held in Berlin, Germany, in support of Gavi’s 2016 – 2020 strategy.

more...
1/21/15 6:45am EST
Pfizer and the Avon Foundation for Women Award 23 Grants Totaling $1 Million in Funding to Support Patients Living With Metastatic Breast Cancer

Today, Pfizer Inc. and the Avon Foundation for Women are proud to announce the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify.

more...
1/8/15 8:30am EST
Pfizer Provides Update on IBRANCE® (palbociclib)

The U.S. Food and Drug Administration (FDA) has informed Pfizer Inc.

more...

Pages